PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer
In this MEDtalk Eric Pujade-Lauraine presents the key results of the study retreatment with maintenance olaparib in patients with ovarian cancer, previously treated with a PARP inhibitor.
